Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975619 | 0.87 | NPC1 (0.37) | TACR1NPC1POLBBACE1MAPT | |
| SCHEMBL3977272 | 0.81 | TACR1 (0.43) | TACR1POLBBACE1MAPTGAA | |
| SCHEMBL3982069 | 0.79 | MEN1 (0.41) | NPC1POLBMAPTGAAKDM4E | |
| SCHEMBL3985267 | 0.75 | MGLL (0.44) | NPC1POLBMAPTGAALMNA | |
| SCHEMBL3977739 | 0.71 | GAA (0.43) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL4279549 | 0.71 | TACR1 (0.41) | TACR1NPC1POLBBACE1MAPT | |
| SCHEMBL3977656 | 0.71 | TACR1 (0.41) | TACR1POLBBACE1MAPTGAA | |
| SCHEMBL3977800 | 0.69 | KDM4E (0.50) | POLBGAAKDM4EMEN1KMT2A | |
| SCHEMBL3977605 | 0.69 | MAPT (0.33) | NPC1POLBMAPTGAAKDM4E | |
| SCHEMBL4282784 | 0.68 | CDC7 (0.45) | GAAKDM4EMEN1KMT2ATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012584-B2 | Cell culture plate, devices and methods for in vitro exposure | PHILIP MORRIS PRODUCTS S.A. (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20200339938-A1 | CELL CULTURE PLATE, DEVICES AND METHODS FOR IN VITRO EXPOSURE | PHILIP MORRIS PRODUCTS S.A. (CH) | 2020-10-29 | — | — | US | disclosed |
| EP-3728547-A1 | IMPROVED CELL CULTURE DEVICE | Philip Morris Products S.a.s. (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200318048-A1 | IMPROVED CELL CULTURE DEVICE | PHILIP MORRIS PRODUCTS S.A. (CH) | 2020-10-08 | — | — | US | disclosed |
| CN-105247053-B | Tobacco specific nitrosamine reduction in plants | 菲利普莫里斯产品有限公司 | 2020-07-31 | — | — | CN | disclosed |
| EP-3676365-A1 | CELL CULTURE PLATE, DEVICES AND METHODS FOR IN VITRO EXPOSURE | Philip Morris Products S.a.s. (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10563215-B2 | Tobacco specific nitrosamine reduction in plants | PHILIP MORRIS PRODUCTS S.A. (CH) | 2020-02-18 | — | — | US | disclosed |
| US-10415050-B2 | Reduction of nicotine to nornicotine conversion in plants | PHILIP MORRIS PRODUCTS S.A. (CH) | 2019-09-17 | — | — | US | disclosed |
| WO-2019043130-A1 | CELL CULTURE PLATE, DEVICES AND METHODS FOR IN VITRO EXPOSURE | PHILIP MORRIS PRODUCTS S.A. (CH) | 2019-03-07 | — | — | WO | disclosed |
| US-20170145431-A1 | MODULATION OF NITRATE CONTENT IN PLANTS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2017-05-25 | — | — | US | disclosed |
| WO-2015197727-A9 | MODULATION OF BIOMASS IN PLANTS BY ECTOPIC EXPRESSION OF A CHLORIDE CHANNEL | PHILIP MORRIS PRODUCTS S.A (CH) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015197727-A2 | MODULATION OF NITRATE CONTENT IN PLANTS | PHILIP MORRIS PRODUCTS S.A (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015169927-A1 | REDUCTION OF NICOTINE TO NORNICOTINE CONVERSION IN PLANTS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315603-A1 | TOBACCO SPECIFIC NITROSAMINE REDUCTION IN PLANTS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2935588-A2 | TOBACCO SPECIFIC NITROSAMINE REDUCTION IN PLANTS | Philip Morris Products S.a.s. (CH) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014096283-A2 | TOBACCO SPECIFIC NITROSAMINE REDUCTION IN PLANTS | PHILIP MORRIS PRODUCTS S.A (CH) | 2014-06-26 | — | — | WO | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20050043515-A1 | Tobacco-specific nitrosamine detection assays and reagents | SWEDISH MATCH NORTH AMERICA, INC. | 2005-02-24 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | TACR1 485/4885NPC1 1584/4885POLB 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.